-
Taxonomy & unit
-
us-gaap: shares
-
Description
-
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
-
Summary
-
Adaptimmune Therapeutics PLC quarterly/annual Weighted Average Number of Shares Outstanding, Diluted history and growth rate from Q3 2017 to Q2 2024.
- Adaptimmune Therapeutics PLC Weighted Average Number of Shares Outstanding, Diluted for the quarter ending June 30, 2024 was 1.56B shares, a 40.7% increase year-over-year.
- Adaptimmune Therapeutics PLC annual Weighted Average Number of Shares Outstanding, Diluted for 2023 was 1.21B shares, a 24.7% increase from 2022.
- Adaptimmune Therapeutics PLC annual Weighted Average Number of Shares Outstanding, Diluted for 2022 was 967M shares, a 3.47% increase from 2021.
- Adaptimmune Therapeutics PLC annual Weighted Average Number of Shares Outstanding, Diluted for 2021 was 935M shares, a 9.37% increase from 2020.
Weighted Average Number of Shares Outstanding, Diluted, Quarterly (shares)
Weighted Average Number of Shares Outstanding, Diluted, YoY Quarterly Growth (%)